“Currently, there is no commercially available adjunctive injectable therapy, outside of a hospital setting, for the emergency treatment of acute repetitive epileptic seizures,” said Michael Jolly, executive vice president of R&D at King. “We believe Vanquix has the potential to effectively address this unmet medical need.”
At present, the only product commercially available for the management of patients with acute, repetitive seizures by a caregiver who is not a healthcare professional is a diazepam rectal gel. This product requires a patient to retain the gel in the rectum for absorption to occur and may be difficult to administer during a seizure. Vanquix is designed to provide a superior means of delivering diazepam to such patients.